Endo International PLC
NASDAQ:ENDP
Intrinsic Value
Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ENDP.
Endo International PLC's market capitalization is 32.3m USD.
ENDP stock price is 0.1374 USD.
ENDP.
ENDP. Open DCF Valuation
ENDP. Open Relative Valuation
ENDP.
ENDP's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 6%.
ENDP has positive Operating Income for the last twelve months.
ENDP's Revenue has dropped by 23% over the past 12 months.
ENDP has positive Free Cash Flow for the last twelve months.
ENDP has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
ENDP has positive three-year average ROE (Return on Equity): 23%. The company is efficient at transforming stockholders' equity into net income.
ENDP has negative Net Income for the last twelve months.
ENDP's ROE (Return on Equity) for the past 12 months is very high and is equal to 70%.
ENDP's long-term liabilties (10B USD) exceed its long-term assets (5B USD).
ENDP has positive Gross Profit for the last twelve months.
ENDP's short-term assets (2B USD) exceed its short-term liabilties (565m USD).
ENDP has positive Net Debt. This means that the company has more debt (8B USD) than cash and short-term investments (866m USD).
ENDP's D/E (Debt to Equity) is very low and is equal to -0.
ENDP's Altman Z-Score is very low and is equal to -2.51.
ENDP doesn't generate enough operating income (260m USD) to safely cover interest payments on its debt (290m USD).
Fundamental Analysis
Endo International PLC
Balance Sheet Decomposition
Endo International PLC
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 1B |
| Receivables | 502.6m |
| Other Current Assets | 555.3m |
| Non-Current Assets | 3.7B |
| PP&E | 466.4m |
| Intangibles | 3.1B |
| Other Non-Current Assets | 129.8m |
| Current Liabilities | 689.6m |
| Accounts Payable | 237.7m |
| Accrued Liabilities | 449.8m |
| Other Current Liabilities | 2.1m |
| Non-Current Liabilities | 9.2B |
| Long-Term Debt | 1.4m |
| Other Non-Current Liabilities | 9.2B |
Earnings Waterfall
Endo International PLC
|
Revenue
|
2.3B
USD
|
|
Cost of Revenue
|
-751.2m
USD
|
|
Gross Profit
|
1.6B
USD
|
|
Operating Expenses
|
-1.3B
USD
|
|
Operating Income
|
259.8m
USD
|
|
Other Expenses
|
-3.2B
USD
|
|
Net Income
|
-2.9B
USD
|
Free Cash Flow Analysis
Endo International PLC
What is Free Cash Flow?
ENDP Profitability Score
Profitability Due Diligence
Endo International PLC's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Endo International PLC's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
ENDP Solvency Score
Solvency Due Diligence
Endo International PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Endo International PLC's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENDP Price Targets Summary
Endo International PLC
Ownership
ENDP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ENDP Price
Endo International PLC
| Average Annual Return | 13.27% |
| Standard Deviation of Annual Returns | 74.88% |
| Max Drawdown | -99% |
| Market Capitalization | 32.3m USD |
| Shares Outstanding | 235 114 000 |
| Percentage of Shares Shorted | 21.67% |
Company Profile
Endo International PLC
Country
Industry
Market Cap
Dividend Yield
Description
Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 3,103 full-time employees. The company went IPO on 2014-03-03. The firm operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, and others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. Its Generic Pharmaceuticals segment consists solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.
You don't have any saved screeners yet
